![]() |
|
|
and
Require Zinc for Their Anti-inflammatory Properties in Porcine Vascular Endothelial Cells1

* Graduate Center for Nutritional Sciences
Department of Surgery and
** Molecular and Cell Nutrition Laboratory, College of Agriculture, University of Kentucky, Lexington, KY 40546-0215
2To whom correspondence should be addressed. E-mail: bhennig{at}uky.edu.
Zinc is an essential structural component of various proteins and is crucial for the integrity of the vascular endothelium. The present study focused on the effect of zinc deficiency on the anti-inflammatory properties of peroxisome proliferator activated receptor (PPAR)
and
agonists. Porcine pulmonary-arterial endothelial cells were deprived from zinc by chelator N,N,N',N'-tetrakis (2-pyridylmethyl)ethylene diamine. Cells were exposed to TNF-
for 2 h following pretreament with the PPAR
agonists fenofibrate or ciprofibrate or the PPAR
agonists thiazolidinedione or troglitazone. The inflammatory response was tested by measuring nuclear factor-kappaB (NF-
B) and activator protein-1 (AP-1) binding activities as well as by measuring mRNA expression levels of inflammatory genes, such as vascular cell adhesion molecule-1 (VCAM-1) and IL-6. All PPAR agonists tested lost their potency to downregulate the TNF-
induced inflammatory response in zinc-deficient cells. However, if zinc was added back, all PPAR agonists significantly downregulated the TNF-
mediated induction of inflammatory transcription factors NF-
B and AP-1 and significantly reduced the expression of their target genes, VCAM-1 and IL-6. We therefore hypothesize that zinc is required for the PPAR
and -
DNA binding activity. Indeed, zinc deficiency significantly reduced the agonist-induced binding activity of PPAR
and -
to the PPAR response element. Our data demonstrate the importance of zinc in PPAR signaling and the requirement of zinc for the anti-inflammatory properties of PPAR
and -
agonists.
KEY WORDS: atherosclerosis vascular endothelial cells PPAR zinc inflammation
This article has been cited by other articles:
![]() |
H. Shen, E. Oesterling, A. Stromberg, M. Toborek, R. MacDonald, and B. Hennig Zinc Deficiency Induces Vascular Pro-Inflammatory Parameters Associated with NF-{kappa}B and PPAR Signaling J. Am. Coll. Nutr., October 1, 2008; 27(5): 577 - 587. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Stadler, N. Stanley, S. Heeneman, V. Vacata, M. J.A.P. Daemen, P. G. Bannon, J. Waltenberger, and M. J. Davies Accumulation of Zinc in Human Atherosclerotic Lesions Correlates With Calcium Levels But Does Not Protect Against Protein Oxidation Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 1024 - 1030. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Shen, R. MacDonald, D. Bruemmer, A. Stromberg, A. Daugherty, X.-a. Li, M. Toborek, and B. Hennig Zinc Deficiency Alters Lipid Metabolism in LDL Receptor Deficient Mice Treated with Rosiglitazone J. Nutr., November 1, 2007; 137(11): 2339 - 2345. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xu, L. Lu, C. Greyson, M. Rizeq, K. Nunley, B. Wyatt, M. R. Bristow, C. S. Long, and G. G. Schwartz The PPAR-{alpha} activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1798 - H1807. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Reiterer, R. MacDonald, J. D. Browning, J. Morrow, S. V. Matveev, A. Daugherty, E. Smart, M. Toborek, and B. Hennig Zinc Deficiency Increases Plasma Lipids and Atherosclerotic Markers in LDL-Receptor-Deficient Mice J. Nutr., September 1, 2005; 135(9): 2114 - 2118. [Abstract] [Full Text] [PDF] |
||||